Form D · Pharmaceuticals
Etheros Pharmaceuticals Corp.
Nashville, TN · CIK 0002005132
Offering snapshot reported Jun 10, 2025 · SEC filing
- Reported sold
- $600K Offering amount: $600K
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Jan 31, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 10, 2025 | Initial | $600,000 | No comparison | 6 | SEC filing |
| Dec 20, 2023 | Initial | $775,000 | No comparison | 5 | SEC filing |
| Dec 20, 2023 | Initial | $300,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-548553
Offering is now closed.
Simple agreement for future equity (SAFE)
Source: Form D, filed Jun 10, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Subhasish Chakraborty | Executive |
| Laura Dugan | Director |
| Marc Feldmann | Director |
| Francis Knuettel | Director |
| Francis Knuettel Ii | Director |
| John William Scannell | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
111 10 Th Ave S Ste 110
Nashville, TN, 37203
Phone: 615-212-9695
Nashville, TN, 37203
Phone: 615-212-9695